Supernus Pharmaceuticals, Inc. SUPN R2K

Healthcare · Drug Manufacturers - Specialty & Generic · United States

https://www.supernus.com

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Market & Price

Market Cap

$2.68B

Current Price

$46.18

High / Low (52W)

$57.00 / $31.16

Beta

0.57

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

10.58

PEG Ratio

Book Value

$18.48

Price to Book

2.50

P/S

3.45

EV/EBITDA

19.06

Dividend Yield

Profitability & Returns

ROCE

-4.40%

ROE

-2.75%

ROA

1.11%

Profit Margin

-3.74%

Op Margin

-3.58%

EPS (Latest Qtr)

$-0.04

EPS (TTM)

$-0.51

Balance Sheet & Liquidity

Debt/Equity

3.80

Quick Ratio

1.51

Current Ratio

1.96

Debt

$40.90M

Total Assets

$1.45B

Current Assets

$644.18M

Working Capital

$306.01M

Ownership

Promoter Holding

4.46%

Chg in Prom Hold

FII / Inst Holding

103.77%

Chg in FII Hold

-0.02%

Financial Snapshot

Enterprise Value

$2.34B

Total Revenue (TTM)

$776.83M

EBITDA

$122.63M

Free Cash Flow

$132.62M

Operating Cash Flow

$83.26M

Shares Outstanding

58.04M

Gross Margin

74.13%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

2.52%

Profit 5Y

-54.50%

Revenue (YoY)

38.60%

Earnings (YoY)

PROS

Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Earnings shrank at -54.5% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	SUPN Supernus Pharmaceuticals, Inc. R2K	46.18	-	$2.68B	-	-4.40%	-2.75%	2.52%	-54.50%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	104.69M	102.14M	-	94.98M	126.73M	155.13M	130.93M	141.33M	148.46M	152.51M	170.05M	177.35M	153.76M	135.56M	153.88M	143.64M	168.32M	-	-	149.82M	165.45M	192.10M	211.57M	207.71M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.76M	16.83M	18.96M	23.01M	23.39M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	134.06M	148.63M	173.14M	188.56M	184.31M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	136.66M	136.49M	233.37M	174.74M	190.25M
Operating Income	3.08M	5.08M	-	6.44M	11.64M	19.84M	16.30M	16.79M	26.07M	22.34M	34.34M	31.39M	35.72M	37.48M	39.85M	25.43M	42.60M	39.73M	40.82M	29.01M	45.55M	56.14M	13.21M	34.11M	32.60M	1.97M	11.35M	-1.52M	5.18M	-17.59M	8.14M	-3.15M	22.57M	-	-	-2.60M	12.14M	-60.23M	13.82M	-5.94M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17.79M	33.50M	-35.42M	26.67M	20.19M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5.83M	16.67M	-57.95M	-1.91M	-5.95M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.00M	-5.83M	-12.84M	2.19M	-3.66M
Net Income	2.44M	3.92M	6.85M	4.83M	10.25M	61.83M	14.32M	10.30M	17.37M	15.96M	13.66M	26.35M	30.74M	28.01M	25.89M	18.34M	32.73M	28.86M	33.13M	21.52M	34.67M	40.00M	5.69M	23.73M	21.56M	25.62M	7.87M	1.75M	16.95M	-831.00K	-15.98M	124.00K	19.92M	-	-	-11.83M	22.50M	-45.12M	-4.11M	-2.29M
Diluted EPS	0.04	0.08	0.14	0.08	0.18	1.18	0.26	0.19	0.32	0.29	0.26	0.49	0.57	0.52	0.48	0.34	0.61	0.54	0.62	0.40	0.65	0.74	0.11	0.43	0.40	0.43	0.14	0.03	0.29	-0.02	-0.29	0.00	0.36	-	-	-0.21	0.40	-0.80	-0.07	-0.04
R&D Expense	6.88M	9.13M	-	10.56M	11.11M	7.87M	-	9.60M	10.82M	12.98M	-	18.91M	20.04M	20.42M	-	15.39M	16.97M	16.94M	-	18.94M	22.25M	16.84M	34.28M	15.46M	19.65M	20.84M	16.39M	19.55M	21.21M	24.38M	22.66M	24.93M	26.18M	29.04M	-	26.93M	22.11M	29.37M	-	39.44M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	408.90M	392.75M	520.40M	-	667.24M	607.52M	661.82M	718.95M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	87.22M	83.78M	77.91M	74.56M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	580.02M	523.74M	583.91M	644.39M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	534.40M	510.34M	508.36M	681.25M
Operating Income	-40.12M	-37.75M	-42.17M	-61.92M	-5.28M	20.84M	54.22M	99.54M	144.44M	148.57M	173.70M	-	45.61M	13.40M	75.56M	-36.86M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	153.36M	90.04M	178.28M	42.53M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	7.07M	2.42M	0	0
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	60.74M	2.77M	97.87M	-49.03M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	32.00K	1.45M	24.00M	-10.48M
Net Income	-38.46M	53.81M	-46.28M	-92.27M	-10.93M	13.94M	91.22M	57.28M	110.99M	113.06M	126.95M	-	60.71M	1.32M	73.86M	-38.55M
Diluted EPS	-	-	-2.72	-2.90	-0.26	0.28	1.76	1.08	2.05	2.10	2.36	-	1.04	0.02	1.32	-0.68
R&D Expense	35.15M	30.63M	23.52M	17.25M	19.59M	29.14M	42.79M	49.58M	89.21M	69.10M	75.96M	90.47M	74.55M	91.59M	108.80M	106.23M

Compounded Sales Growth

5 Years:	2.52%
1 Year:	38.60%

Compounded Profit Growth

5 Years:	-54.50%
1 Year:	-

Stock Price Performance

1 Year:	+45.68%
6 Months:	+0.22%
3 Months:	-15.62%
1 Month:	-4.88%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	53.73M	93.99M	111.00M	137.51M	188.63M	309.57M	424.46M	977.81M	1.16B	1.50B	-	1.70B	1.28B	1.37B	1.45B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	734.15M	493.11M	686.07M	644.18M
Cash & Equivalents	31.41M	23.74M	48.54M	40.30M	32.98M	36.40M	33.50M	66.40M	100.30M	192.25M	181.38M	288.64M	-	93.12M	75.05M	69.33M	128.45M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	91.54M	77.41M	54.29M	82.39M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	165.50M	144.16M	142.08M	187.80M
Total Liabilities	-	-	44.29M	36.42M	77.53M	66.15M	100.62M	117.81M	156.98M	524.79M	564.85M	759.24M	-	816.30M	356.16M	332.34M	390.93M
Current Liabilities	-	-	18.77M	22.98M	26.40M	27.49M	56.93M	80.74M	123.00M	161.35M	160.59M	245.11M	-	687.96M	290.20M	292.40M	338.17M
Long Term Debt	-	-	-	23.23M	-	-	-	-	-	-	-	-	379.25M	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	444.76M	41.53M	34.27M	40.98M
Total Equity	-6.16M	-44.32M	9.44M	57.57M	33.46M	40.70M	88.01M	191.75M	267.48M	453.02M	595.43M	744.86M	-	886.20M	921.52M	1.04B	1.06B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	54.25M	54.72M	55.74M	57.46M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-32.54M	-36.19M	-47.20M	-57.95M	7.73M	34.52M	66.81M	114.64M	128.99M	143.13M	138.40M	-	116.83M	111.08M	171.95M	47.33M
Investing Cash Flow	25.82M	33.90M	-48.96M	-12.11M	-4.89M	-39.29M	-35.96M	-86.42M	-413.48M	-157.92M	-34.70M	-	-216.66M	268.73M	-189.87M	4.11M
Financing Cash Flow	-944.00K	27.09M	87.92M	62.74M	570.00K	1.87M	2.05M	5.68M	376.44M	3.93M	3.56M	-	-10.48M	-397.88M	12.19M	9.13M
Capital Expenditure	-294.00K	-685.00K	-753.00K	-1.65M	-593.00K	-2.10M	-1.60M	-2.03M	-844.00K	-2.74M	-3.45M	-	-412.00K	-551.00K	-725.00K	-1.34M
Free Cash Flow	-32.84M	-36.87M	-47.95M	-59.59M	7.14M	32.42M	65.21M	112.61M	128.14M	140.39M	134.95M	-	116.41M	110.53M	171.23M	45.99M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-110.31M	-18.07M	-5.72M	60.57M

Ratios (Annual)

Figures in %.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	86.9%	86.2%	88.2%	89.6%
Operating Margin %	-	-	-	-	-	-	-	-	35.3%	37.8%	33.4%	-	6.8%	2.2%	11.4%	-5.1%
Net Margin %	-	-	-	-	-	-	-	-	27.1%	28.8%	24.4%	-	9.1%	0.2%	11.2%	-5.4%
ROE %	86.8%	569.9%	-80.4%	-275.7%	-26.8%	15.8%	47.6%	21.4%	24.5%	19.0%	17.0%	-	6.9%	0.1%	7.1%	-3.6%
ROCE %	-	-108.0%	-59.4%	-73.2%	-4.8%	15.8%	23.7%	33.0%	17.7%	14.9%	13.8%	-	4.5%	1.4%	7.0%	-3.3%

Shareholding Pattern

Insiders

4.46%

Institutions

103.77%

Public Float

108.62%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	15.16%	8.80M	$406.26M
2	Millennium Management Llc	5.71%	3.32M	$153.13M
3	Vanguard Portfolio Management LLC	5.58%	3.24M	$149.56M
4	Vanguard Capital Management LLC	4.25%	2.47M	$113.94M
5	Dimensional Fund Advisors LP	3.97%	2.31M	$106.54M
6	State Street Corporation	3.94%	2.29M	$105.67M
7	Nomura Asset Management International Inc	3.51%	2.04M	$94.08M
8	Armistice Capital, LLC	3.27%	1.90M	$87.53M
9	Renaissance Technologies, LLC	2.94%	1.71M	$78.75M
10	Geode Capital Management, LLC	2.80%	1.62M	$74.97M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SUPN

No recent headlines available.

SUPN · Healthcare